Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

InterMune, Roche form new danoprevir deal valued at $175mm

Executive Summary

Four years after forming a global development and US co-promotion agreement with Roche for its hepatitis C protease inhibitor danoprevir, InterMune Inc. (respiratory and infectious disease therapeutics) has decided to cease its investment in the drug candidate, thereby terminating that 2006 deal. Roche now has sole ownership, holding worldwide development and commercialization rights.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Product Purchase

Related Companies